Radioactive drug targets Hard-to-Treat thyroid cancer
NCT ID NCT06991738
First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 3 times
Summary
This study tests a radioactive drug called 177Lu-DOTA-EB-TATE in 18 adults with a rare thyroid cancer (Hurthle cell) that has spread and not responded to standard radioactive iodine treatment. The drug is designed to seek out and attach to cancer cells. Participants will receive four infusions over several months and be monitored for safety and effectiveness. The goal is to find a safe dose that can slow or stop the cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
177Lu-DOTA-EB-TATE (a radioactive drug that targets cancer cells)
What this could lead to
If it works, this could offer a new treatment option for people with a rare thyroid cancer that has few alternatives.
What could go wrong
This is a very early, small trial (18 people) focused on finding a safe dose. It may not work or could have side effects from radiation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYROID CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••